|CD27 is a member of the tumor necrosis factor (TNF) receptor superfamily, which includes the T cell co-stimulatory receptors OX40, 4-1BB and herpesvirus entry mediator (HVEM). CD27 is expressed on various types of T cells, B cells and a subset of natural killer cells. It activates NF- kB and MAPK/JNK signaling upon interaction with its TNF-like ligand, CD70, which is expressed by numerous tumor cells. Adaptor proteins TRAF2 and TRAF5 can also stimulate CD27 signaling. Activation of CD27 leads to lymphoid proliferation, differentiation, apoptosis, and the induction of long-term memory. The CD27/CD70 pathway is a key target for the development of treatments for cancer and inflammatory diseases.|
CHO cell line expressing full length human CD27 (TNFRSF7). Expression is confirmed by real time qPCR, Western blot, and flow cytometry.
Screening for antibodies recognizing CD27 and screening antibodies for binding affinities. Since CHO cells do not express endogenous CD27, this cell line serves as an excellent model for studying changes in CD27-mediated signaling pathways, such as NF-kB, MAPK and SAPK/JNK.
|Stability:||32 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.)|
|Synonym(s):||CD70 antigen, Tumor Necrosis Factor Ligand Superfamily Member 7, TNFSF7, CD27 Ligand, Ki-24 antigen, CD27-L, CD27LG|
|Freeze Medium:||90% FBS+10% DMSO|
|IV. Description of Host Cell Line|
|Organism:||Cricetulus griseus, hamster, Chinese|
|Ⅴ. Representative Data|
Figure 1. Recombinant CHO cell line expressing full length human CD27 (TNFRSF7). Expression is confirmed by flow cytometry.